MAP3K7CL: A Potential Drug Target and Biomarker (G56911)

Target Name: MAP3K7CL

NCBI ID: G56911

MAP3K7CL

MAP3K7CL: A Potential Drug Target and Biomarker

MAP3K7CL, also known as MAP3K7CL-like, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the MAPK/ERK signaling pathway, which is a well-established pathway that regulates various cellular processes in the cell, including cell growth, differentiation, and survival.

MAP3K7CL is composed of 21 amino acid residues and has a calculated molecular weight of 11.4 kDa. It is expressed in a variety of tissues, including the brain, heart, and lungs, and has been shown to be involved in various cellular processes, including cell signaling, cell adhesion, and cell survival.

One of the most interesting aspects of MAP3K7CL is its potential as a drug target. The MAPK/ERK signaling pathway has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, targeting MAP3K7CL or its downstream signaling pathways may be a promising strategy for the development of new treatments for these diseases.

MAP3K7CL has also been shown to play a role in cell signaling and cell adhesion. It is a member of the Integrin alpha-2 (Integrin-伪2) complex, which is a critical receptor for cell adhesion and signaling. This suggests that MAP3K7CL may be involved in the regulation of cell-cell interactions and may be a useful target for drugs that are designed to modulate cell signaling.

MAP3K7CL is also known to be involved in the regulation of cell survival. Its expression has been shown to be associated with the survival of various cell types, including cancer cells. This suggests that targeting MAP3K7CL may be a useful strategy for the treatment of cancer.

In addition to its potential as a drug target, MAP3K7CL is also of interest as a biomarker. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, measuring the expression of MAP3K7CL may be a useful diagnostic tool for these diseases and may also be a target for diagnostic biomarkers.

In conclusion, MAP3K7CL is a protein that is expressed in various tissues of the body and is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of MAP3K7CL in these processes and to develop effective treatments.

Protein Name: MAP3K7 C-terminal Like

The "MAP3K7CL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP3K7CL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets